2024年第47届圣安东尼奥乳腺癌研讨会(San Antonio Breast Cancer Symposium,SABCS)将于12月10日至13日在美国得克萨斯州圣安东尼奥举行。该会议汇聚了全球约1万名临床医生和专家,是规模最大、最具影响力的乳腺癌研究盛会。
日前,大会公布了本次会议的详细日程,为进一步与大家分享和学习最新的会议资讯内容,【肿瘤资讯】特将12月10日的会议日程进行整理,便于读者了解此次会议的整体概况。
辅助教育活动
Ancillary Educational Events
(仅限现场,不提供线上或虚拟观看)
时间:12月10日 8:00 – 9:15 am(Central Time)(本文均为美国中央时间)
柳叶刀乳腺癌专场
Lancet Breast Cancer Session
时间:12月10日 9:30 – 11:30 am
ABC Global Alliance 与 US MBC Alliance 交流专场
ABC Global Alliance and US MBC Alliance Communication Session
风险降低与早期检测:肥胖相关乳腺癌风险的机制及降低风险的方法
Risk Reduction and Early Detection: Mechanisms of Obesity Related Risk for Breast Cancer and Approaches to Risk Reduction
地点和时间:Hemisfair Ballroom 1-2,12月10日 12:00 – 1:45 pm
主持人:Carol Fabian, University of Kansas Medical Center, Westwood, Kansas
对热量限制和体力活动反应的遗传和表观遗传变化
Genetic and Epigenetic Changes in Response to Caloric Restriction and Physical Activity
Catherine Duggan, Fred Hutchinson Cancer Center, Seattle, Washington
实现足够的脂肪减少和代谢改善以降低癌症风险:基于新一代GLP-1n和GIP受体激动剂(营养感知激素[NUSH])的疗法
Achieving Sufficient Fat Loss and Metabolic Improvement to Reduce Cancer Risk: Newer Generation GLP-1n and GIP Receptor Agonists (Nutrient Sensing Hormone (NUSH) - Based Therapeutics
Neil Iyengar, Memorial Sloan Kettering Cancer Center, New York, New York
运动和药物治疗在减重中的作用和类型
Impact and Types of Exercise and Pharmacotherapy in Weight Loss
John Jakicic, University of Kansas Medical Center, Westwood, Kansas
• Panel Discussion
FDA特别专场:新药获批
FDA Special Session: New Drug Approvals
地点和时间:Stars at Night 3-4,12月10日 12:00 – 1:45 pm
主持人:Laleh Amiri Kordestani, FDA, Silver Spring, Maryland, and Eric Winer, Yale University, New Haven, Connecticut.
Patient Advocate: Victoria Goldberg, New York, New York
辅助瑞波西利
Adjuvant Ribociclib
Jennifer Gao, FDA, Silver Spring, Maryland
• Panel Discussion
Inavolisib(伊那利塞)获批
Inavolisib Approval
Suparna Wedam, FDA, Silver Spring Maryland
• Panel Discussion
临床试验中卵巢毒性的监测
Monitoring of Ovarian Toxicity During Clinical Trials
Antonio Wolff, Sidney Kimmel Comprehensive Cancer Center, Baltimore,Maryland
• Panel Discussion
特别专场3:性别、药物、活力与创新
Special Session 3: Sex, Drugs, Rock and Roll
地点和时间:Stars at Night 1-2,12月10日 12:00 – 1:45 pm
主持人:Christine Ambrosone, Roswell Park Comprehensive Cancer Center, Buffalo, New York
Patient Advocate: Tomika Bryant, King of Prussia, Pennsylvania
补充剂和大麻
Supplements and Cannabis
Heather Greenlee, Fred Hutchinson Cancer Center, Seattle, Washington
性健康
Sexual Health
Don Dizon, Legorreta Cancer Center at Brown University/Lifespan Cancer Institute, Providence, Rhode Island
治疗期间的运动
Exercise During Treatment
Rikki Cannioto, Roswell Park Comprehensive Cancer Center, Buffalo, New York
饮食与饮酒
Eating and Drinking
Lawrence Kushi, Kaiser Permanente Northern California, Pleasanton,California
• Panel Discussion
职业发展:通往成功的道路—早期研究资助及其他
Career Development: Navigating the Road to Success - Early Funding for Research and Beyond
地点和时间: Room 221ABC,12月10日 12:00 – 1:45 pm
主持人:Brenda Ernst, Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona
联邦资助机会
Federal Funding Opportunities
Larissa Korde, Johns Hopkins School of Medicine, Washington, D.C.
基金会和社区项目支持
Foundation and Community Program Support
Sara Tolaney, Dana-Farber Cancer Institute, Boston, Massachusetts
行业互动和资助项目
Industry Interactions and Funding Programs
Minetta Liu, Natera, Austin, Texas
• Panel Discussion
临床研讨会:乳腺肿瘤医学中的剂量优化
Clinical Workshop: Dose Optimization in Breast Medical Oncology
地点和时间:Stars at Night 1-2,12月10日 2:00 – 3:45 pm
主持人:Mirat Shah, FDA, Silver Springs, Maryland, and Patricia LoRusso, Yale School of Medicine, New Haven, Connecticut
Speakers and Panelists: Stacy Shord, Julia Maues, Mallorie Fiero, and Michael Ignatiadis
Part A:
为什么是现在?肿瘤学中剂量优化的必要性
Why Now? The Need for Dosage Optimization in Oncology.
Patricia LoRusso, Yale School of Medicine, New Haven, Connecticut
剂量优化的细节和基础
The Nuts and Bolts of Dosage Optimization
Stacy Shord, FDA, Silver Springs, Maryland
什么是方案优化?为什么我们需要它?
What is Regimen Optimization and Why do We Need It
Mirat Shah, FDA, Silver Springs, Maryland
现实剂量:患者视角
A Dose of Reality: The Patient Perspective
Julia Maues, Patient Advocate, Baltimore, Maryland Discussion/Q&A: Everyone
Part B:
临床试验设计中的交叉缺失
Lack of Crossover in Clinical Trial Design
Michael Ignatiadis, Institut Jules Bordet, Brussels, Belgium
• Discussion/Q&A: Everyone
转化研讨会:癌症免疫学发现转化为临床试验
Translational Workshop: Cancer Immunology Discovery Approaches into Clinical Trials
地点和时间:Stars at Night 3-4,12月10日 2:00 – 3:45 pm
主持人:Christine Desmedt, KU Leuven, Leuven, Belgium
多重成像技术在精准肿瘤学中的应用
Multiplex Imaging for Precision Oncology
Raza Ali, Cancer Research UK, Cambridge, United Kingdom
单细胞T细胞受体和B细胞受体
Single Cell T-Cell Receptors and B-Cell Receptors
Diether Lambrechts, Catholic University of Leuven, Leuven, Belgium
空间转录组学
Spatial Transcriptomics
Christos Sotirou, Institut Jules Bordet, Brussels, Belgium
癌症免疫学发现方法在临床试验中的应用
Cancer Immunology Discovery Approaches into Clinical Trials
Emanuela Romano, Institut Curie, Paris, France
• Panel Discussion
职业发展:患者驱动方案开发
Career Development: Patient Driven Protocol Development
地点和时间:Room 221ABC,12月10日 2:30 – 4:00 pm
主持人:Saranya Chumsri, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida, and Brenda Ernst, Mayo Clinic Comprehensive Cancer Center, Phoenix, Arizona
Patient Advocate: Debora Denardi, Miami Beach, Florida
临床研究中合作伙伴关系的重要性
Importance of Partnerships in Clinical Research
Edith Perez, Mayo Clinic, Kenwood, California
设计以患者为中心的临床试验
Designing Patient-centric Clinical
Trials Tatiana Prowell, FDA, Silver Spring, Maryland
新颖的统计设计:将患者放在首位
Novel Statistical Designs: Putting Patients First
Amylou Dueck, Mayo Clinic Cancer Center, Scottsdale, Arizona
教育专场1:关注差距—年轻乳腺癌患者
Educational Session 1: Mind the Gap — Breast Cancer in the Young
地点和时间:Stars at Night 1-2,12月10日 4:00 – 5:45 pm
主持人:Matteo Lambertini, University of Genova - IRCCS Ospedale Policlinico, San Martino, Genoa, Italy
Patient Advocate: Na'Diah Smith, Dallas, Texas
年轻女性乳腺癌的生物学特征
Biology of Breast Cancer in Young Women
Camila Dos Santos, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York
卵巢抑制:谁、何时、为何以及持续多久
Ovarian Suppression: Who, When, Why, and for How Long
Prudence Francis, Peter MacCallum Cancer Centre, Melbourne, Australia
幸存者
Survivorship
Jennifer Sheng, Johns Hopkins University, Baltimore, Maryland
• Panel Discussion
教育专场2:液体活检:MRD、ctDNA和治疗反应监测
Educational Session 2: Liquid Biopsy: MRD, CT DNA, and Monitoring Response to Treatment
地点和时间:Hemisfair Ballroom 1-2,12月10日 4:00 – 5:45 pm
主持人:Adrian Lee, University of Pittsburgh, Pittsburgh, Pennsylvania
Patient Advocate: Ellen Landsberger, New York City, New York
当前技术综述
Review of Current Technologies
Heather Parsons, Dana-Farber Cancer Institute, Boston, Massachusetts
早期检测与分子复发性疾病
Early Detection and Molecular Recurrent Disease
Ben Park, Vanderbilt University Medical Center, Nashville, Tennessee
在转移性环境中的效用
Utility in the Metastatic Setting
David Cescon, UHN Princess Margaret Cancer Centre, Toronto, Canada
• Panel Discussion
教育专场3:肿瘤异质性和演变
Educational Session 3: Tumor Heterogeneity and Evolution
地点和时间:Hemisfair Ballroom 3,12月10日 4:00 – 5:45 pm
主持人:Reuben S. Harris, UT Health San Antonio, San Antonio, Texas
正常乳腺组织中非整倍体上皮细胞的鉴定
Identification of Aneuploid Epithelial Cells in Normal Breast Tissues
Nicholas Navin, MD Anderson Cancer Center, Houston, Texas
乳腺癌进展的基因组和微环境决定因素
Genomic and Microenvironment Determinants of Breast Cancer Progression
Christina Curtis, Stanford University, Stanford, California
三阴性乳腺癌中的单细胞基因组学
Single Cell Genomics in Triple Negative Breast Cancer
Ashley Laughney, Weill Cornell Medicine, New York, New York
• Panel Discussion
教育专场4:优化早期HER2阳性乳腺癌治疗
Educational Session 4: Optimizing Early HER2 Positive Breast Cancer Treatment
地点和时间:Stars at Night 3-4,12月10日 4:00 – 5:45 pm
主持人:Javier Cortés, International Breast Cancer Center (IBCC), Pangaea Oncology, Quiron Group, Barcelona, Spain
Patient Advocate: Thelma Brown, Birmingham, Alabama
新辅助管理与适应性策略
Neoadjuvant Management and Adaptive Strategies
Gabe Sonke, Netherlands Cancer Institute, Amsterdam, Netherlands
早期阶段小肿瘤的治疗
Treatment of Small Tumors in Early-Stage Setting
Adrienne Waks, Dana-Farber Cancer Institute, Boston, Massachusetts
非pCR患者的新辅助治疗后管理
Post Neoadjuvant Management for non pCR
Joyce O'Shaughnessy, Baylor-Sammons Cancer Center, Dallas, Texas
• Panel Discussion
茶歇与交流
Refreshment and Networking Break
地点:Main Lobby
最新口头报告专场
Late-Breaking Oral Presentations
地点和时间:Stars at Night 1-2,12月10日 6:00 – 7:00 pm
主持人:Rita Nanda, University of Chicago Medicine, Chicago, Illinois
可手术乳腺癌患者省略即刻手术或减少手术范围的长期影响:对四项随机试验2,514名女性患者水平的荟萃分析
LB1-01: Long-term effects of the omission of immediate surgery in operable breast cancer, or reduction of surgical extent: patient-level meta-analysis of the four randomised trials among 2,514 women.
Robert Hills, University of Oxford, Oxford, United Kingdom
MARGOT/TBCRC052:一项随机II期试验,比较新辅助紫杉醇/ margetuximab /帕妥珠单抗(TMP)与紫杉醇/曲妥珠单抗/帕妥珠单抗(THP)在II-III期HER2阳性乳腺癌患者中的疗效
LB1-02: MARGOT/TBCRC052: A randomized phase II trial comparing neoadjuvant paclitaxel/margetuximab/pertuzumab (TMP) vs paclitaxel/trastuzumab/pertuzumab (THP) in patients (pts) with stage II-III HER2+ breast cancer.
Adrienne Waks, Dana-Farber Cancer Institute, Boston, Massachusetts
PADMA研究:比较一线ET联合哌柏西利 vs标准单药化疗用于具有化疗指征的高危HER2-/HR+转移性乳腺癌患者随机III期试验主要结果
LB1-03: Primary results of the randomised Phase III trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-/HR+ metastatic breast cancer and indication for chemotherapy - PADMA study.
Sibylle Loibl, German Cooperative Group, Neu-Isenburg, Germany
DESTINY-Breast06额外分析:根据既往以内分泌治疗为基础的方案疾病进展速度比较德曲妥珠单抗(T-DXd) vs 医生选择的化疗(TPC)的疗效和安全性
LB1-04: Efficacy and safety of trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) by pace of disease progression on prior endocrine-based therapy: additional analysis from DESTINY-Breast06.
Aditya Bardia, UCLA David Geffen School of Medicine, Los Angeles, California
SOLTI VALENTINE主要结果:一项新辅助随机II期试验旨在评估HER3-DXd单药或与来曲唑联合用于高危HR+/HER2-早期乳腺癌(EBC)的疗效
LB1-06: Primary results of SOLTI VALENTINE: neoadjuvant randomized phase II trial of HER3-DXd alone or in combination with letrozole for high-risk hormone receptor positive (HR+)/HER2-negative (neg) early breast cancer (EBC).
Mafalda Oliveira, Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain
帕博利珠单抗或安慰剂+化疗新辅助治疗,后帕博利珠单抗或安慰剂辅助治疗用于早期三阴性乳腺癌:III期KEYNOTE-522研究探索性生物标志物分析
LB1-07: Exploratory Biomarker Analysis of the Phase 3 KEYNOTE-522 Study of Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage TNBC.
Joyce O’Shaughnessy, Baylor-Sammons Cancer Center, Dallas, Texas
本文整理自SABCS官网公布的信息,不代表名单为实际现场参会专家。若有任何遗漏或错误,可联系我们进行修改。
排版编辑:肿瘤资讯-Jenny